Furthermore, Czyzewski and Styczynski [112] demonstrated that imatinib was a substrate for ABCC1/MRP1 and that it could increase the expression of ABCC1/MRP1, which played a role in imatinib resistance in CML. The gene discussed is ABCC1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.